RESPIRE 1: a phase III placebo-controlled randomised trial of ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis

We evaluated the efficacy and safety of ciprofloxacin dry powder for inhalation (DPI) in patients with non-cystic fibrosis bronchiectasis, two or more exacerbations in the previous year and pre-defined bacteria in sputum. In this phase III, double-blind, placebo-controlled trial, patients were randomised 2:1 to twice-daily ciprofloxacin DPI 32.5 mg or placebo in two treatment regimens consisting of on/off treatment cycles of 14 or 28 days for 48 weeks. The primary end-points were time to first exacerbation and frequency of exacerbations. A total of 416 patients were randomised to the 14-day on/off regimen (ciprofloxacin DPI (n=137) and placebo (n=68)) or the 28-day on/off regimen (ciprofloxacin DPI (n=141) and placebo (n=70)). Ciprofloxacin DPI 14 days on/off significantly prolonged time to first exacerbation versus pooled placebo (median time >336 versus 186 days; hazard ratio 0.53, 97.5% CI 0.36–0.80; p=0.0005) and reduced the frequency of exacerbations compared with matching placebo by 39% (mean number of exacerbations 0.6 versus 1.0; incidence rate ratio 0.61, 97.5% CI 0.40–0.91; p=0.0061). Outcomes for ciprofloxacin DPI 28 days on/off were not statistically significantly different from placebo. The safety profile of ciprofloxacin DPI was favourable. Ciprofloxacin DPI was well tolerated and has the potential to be an effective treatment option in non-cystic fibrosis bronchiectasis. In RESPIRE 1, 14-day on/off cycles of ciprofloxacin dry powder for inhalation reduced bronchiectasis exacerbations http://ow.ly/po4s30gNfl0

[1]  Katrin Roth,et al.  The RESPIRE trials: Two phase III, randomized, multicentre, placebo-controlled trials of Ciprofloxacin Dry Powder for Inhalation (Ciprofloxacin DPI) in non-cystic fibrosis bronchiectasis. , 2017, Contemporary clinical trials.

[2]  A. Smyth,et al.  Aerosolized antibiotic therapy for chronic cystic fibrosis airway infections: continuous or intermittent? , 2011, Respiratory medicine.

[3]  D. Elbourne,et al.  Systematic review of the Hawthorne effect: New concepts are needed to study research participation effects☆ , 2014, Journal of clinical epidemiology.

[4]  H. Stass,et al.  Safety and pharmacokinetics of ciprofloxacin dry powder for inhalation in cystic fibrosis: a phase I, randomized, single-dose, dose-escalation study. , 2015, Journal of aerosol medicine and pulmonary drug delivery.

[5]  H. Stass,et al.  Ciprofloxacin Dry Powder for Inhalation in Patients with Non-Cystic Fibrosis Bronchiectasis or Chronic Obstructive Pulmonary Disease, and in Healthy Volunteers. , 2017, Journal of aerosol medicine and pulmonary drug delivery.

[6]  D. Mannino.  COPD as a disease of children: hype or hope for better understanding? , 2010, Thorax.

[7]  R. Coll,et al.  Diagnóstico y tratamiento de las bronquiectasias , 2008 .

[8]  J. Weers,et al.  The PulmoSphere™ platform for pulmonary drug delivery. , 2014, Therapeutic delivery.

[9]  P. Jones,et al.  Validation of the St. George's Respiratory Questionnaire in bronchiectasis. , 1997, American journal of respiratory and critical care medicine.

[10]  I. Du Rand,et al.  Introduction and methods: British Thoracic Society pleural disease guideline 2010 , 2010, Thorax.

[11]  C. Olveira,et al.  Annual direct medical costs of bronchiectasis treatment , 2016, Chronic respiratory disease.

[12]  P. Flume.  A role for aerosolized antibiotics , 2008 .

[13]  F. Thien,et al.  Chronic suppurative lung disease and bronchiectasis in children and adults in Australia and New Zealand. A position statement from the Thoracic Society of Australia and New Zealand and the Australian Lung Foundation , 2010 .

[14]  T. Welte,et al.  Pulmonary exacerbation in adults with bronchiectasis: a consensus definition for clinical research , 2017, European Respiratory Journal.

[15]  C. Olveira,et al.  Multidimensional approach to non-cystic fibrosis bronchiectasis: the FACED score , 2012, European Respiratory Journal.

[16]  A. Hill,et al.  Short- and long-term antibiotic treatment reduces airway and systemic inflammation in non-cystic fibrosis bronchiectasis. , 2012, American journal of respiratory and critical care medicine.

[17]  D Bilton,et al.  British Thoracic Society guideline for non-CF bronchiectasis , 2010, Thorax.

[18]  P. Thompson,et al.  Aztreonam for inhalation solution in patients with non-cystic fibrosis bronchiectasis (AIR-BX1 and AIR-BX2): two randomised double-blind, placebo-controlled phase 3 trials. , 2014, The Lancet. Respiratory medicine.

[19]  E. Stovold,et al.  Inhaled antibiotics for stable non-cystic fibrosis bronchiectasis: a systematic review , 2014, European Respiratory Journal.

[20]  Stefano Aliberti,et al.  The bronchiectasis severity index. An international derivation and validation study. , 2014, American journal of respiratory and critical care medicine.

[21]  StassHeino,et al.  Safety and Pharmacokinetics of Ciprofloxacin Dry Powder for Inhalation in Cystic Fibrosis: A Phase I, Randomized, Single-Dose, Dose-Escalation Study , 2015 .

[22]  T. Welte,et al.  Ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis: a phase II randomised study , 2012, European Respiratory Journal.

[23]  G. Maguire,et al.  Chronic suppurative lung disease and bronchiectasis in children and adults in Australia and New Zealand. A position statement from the Thoracic Society of Australia and New Zealand and the Australian Lung Foundation , 2010 .